Drug Profile

EXV 801

Alternative Names: EXV-801

Latest Information Update: 09 Jan 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Exciva GmbH
Class Behavioural disorder therapies
Mechanism of Action Cytochrome P-450 CYP2D6 inhibitors; Serotonin 2A receptor inverse agonists; Serotonin 2C receptor inverse agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

16 Dec 2025 Exciva GmbH plans the phase II/III SERENADA trial for Alzheimer's disease, in January 2026 (EudraCT2024-517388-22-00), (NCT07284472)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com